Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization

Pharmacotherapy

Volumn 25, Issue 3, 2005, Pages 345-351

  Shanahan, Roberta L ^a,g   Kerzee, Jane A ^b,f   Sandhoff, Brian G ^c,f   Carroll, Nikki M ^d   Merenich, John A ^e,f  

^a Cardiac Risk Service   (United States)

^b Primary Care   (United States)

^c Clinical Pharmacy Cardiac Risk Service   (United States)

^d Clinical Research Unit   (United States)

^e Kaiser Permanente   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g NONE   (United States)

Author keywords

Antidyslipidemic agents; Drug interactions; Myopathy; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CLOFIBRATE; CREATINE KINASE; CYTOCHROME P450 3A4; DELAVIRDINE; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; MEVINOLIN; NELFINAVIR; NICARDIPINE; NIFEDIPINE; PRAVASTATIN; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; POLYMYOSITIS; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SOFT TISSUE DISEASE;

ADULT; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MUSCULAR DISEASES; POLYPHARMACY; RETROSPECTIVE STUDIES;

EID: 14544278807     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.3.345.61606     Document Type: Article

References (11)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
2. The Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
3. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1616-22.
4. Heart Protection Collaborative Group. MRC/BHF heart protections study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22.
5. Roberts WC. Getting more people on statins. Am J Cardiol 2002;90:683-5.
6. Garnett WR. Interactions with hydroxy methylglutaryl coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995;52:1639-44.
7. Alvarez JM, Rawdanowiz TJ, Goldstein J. Rhabdomyolysis after coronary artery bypass grafting in a patients receiving simvastatin. J Thorac Cardiovasc Surg 1998;116:654-5.
8. Kogan AD, Orenstein S. Lovastatin induced acute rhabdomyolysis. J Postgrad Med 1996;66:294-6.
9. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:568-73.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
11. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003;163:688-92.